www.terrascend.com NOVEM BER 2 019 Investors and prospective - - PowerPoint PPT Presentation

www terrascend com
SMART_READER_LITE
LIVE PREVIEW

www.terrascend.com NOVEM BER 2 019 Investors and prospective - - PowerPoint PPT Presentation

www.terrascend.com NOVEM BER 2 019 Investors and prospective investors should rely only on the information contained in the disclosure filings (the Filings) of TerrAscend Corp. (the Company) . This presentation is qualified in its


slide-1
SLIDE 1

www.terrascend.com

NOVEM BER 2 019

slide-2
SLIDE 2

p.2

SEPTEMBER 2019

  • p. 2

P R I V A T E & C O N F I D E N T I A L A P R I L 2 0 1 9 NOVEMBER 2019

  • p. 2

Investors and prospective investors should rely only on the information contained in the disclosure filings (the “Filings”) of TerrAscend Corp. (the “Company”). This presentation is qualified in its entirety by reference to, and must be read in conjunction with, the information contained in Filings. An investor or prospective investor is not entitled to rely on parts of the information contained in this presentation to the exclusion of others, and the Company is not authorized to provide different or additional information. An investment in the securities discussed in this presentation is speculative and subject to a number of risks that should be considered by an investor or prospective investor. Investors and prospective investors should carefully consider the risks described in the Filings. This presentation does not constitute an offering of securities and the information contained herein is subject to the information contained in the Filings. Unless otherwise specified, all monetary amounts in this presentation are in Canadian dollars. Forward-Looking Information This presentation contains forward-looking information or statements within the meaning of applicable securities laws. Forward-looking information may relate to the Company’s future outlook and anticipated events, plans or results, and may include information regarding the Company’s objectives, goals, strategies, future revenue or performance and capital expenditures, and other information that is not historical information. Particularly, information regarding the Company’s expectations of performance, achievements, prospects or opportunities, or the markets in which the Company operates, is forward-looking information. Forward-looking information can often be identified by the use of terminology such as “believe,” “anticipate,” “plan,” “expect,” “pending,” “in process,” “intend,” “estimate,” “project,” “may,” “will,” “should,” “would,” “could,” “can,” the negatives thereof, variations thereon and similar expressions. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events

  • r circumstances contain forward-looking information. Forward-looking information contained in this presentation is based on the Company’s opinions, estimates and assumptions in light of management’s experience and perception of historical trends, current

conditions and expected future developments, as well as other factors that management currently believes are appropriate and reasonable in the circumstances. The forward-looking information contained in this presentation represents the Company’s expectations as of the date of this presentation or the date indicated, regardless of the time of delivery of the presentation. All of the forward-looking information contained in this presentation is expressly qualified by the foregoing cautionary statements. Potential investors should consult their own professional advisors to ascertain and assess the income tax, legal, risk factors and other aspects of their potential investment in the Company. Risk factors that could cause actual results to differ materially from forward-looking information in this presentation include: the Company’s exposure to legal and regulatory risk; the effect of the legalization of adult-use cannabis in jurisdictions where the Company

  • perates on the medical cannabis industry is unknown and may significantly and negatively affect the Company’s medical cannabis business; that the medical benefits, viability, safety, efficacy, dosing and social acceptance of cannabis are not as currently

expected; that adverse changes or developments affecting the Company’s main or planned facilities may have an adverse effect on the Company; that the medical cannabis industry and market may not continue to exist or develop as anticipated or the Company may not be able to succeed in this market; risks related to market competition; risks related to the proposed adult-use and medical cannabis industries and markets including the Company’s ability to enter into or compete in such markets; that the Company has a limited operating history and a history of net losses and that it may not achieve or maintain profitability in the future; risks related to the Company’s current or proposed international operations; risks related to future third party strategic alliances or the expansion of currently existing relationships with third parties; that the Company may not be able to successfully identify and execute future acquisitions or dispositions or successfully manage the impacts of such transactions on its operations; risks inherent to the

  • peration of an agricultural business; that the Company may be unable to attract, develop and retain key personnel; risks resulting from significant interruptions to the Company’s access to certain key inputs such as raw materials, electricity, water and other utilities;

that the Company may be unable to transport its cannabis products to patients in a safe and efficient manner; risks related to recalls of the Company’s cannabis products or product liability or regulatory claims or actions involving the Company’s cannabis products; risks related to the Company’s reliance on pharmaceutical distributors, suppliers and skilled labor; that the Company, or the cannabis industry more generally, may receive unfavourable publicity or become subject to negative consumer or investor perception; that certain events or developments in the cannabis industry more generally may impact the Company’s reputation or its relationships with customers or suppliers; risks related to insurance; that the Company may become subject to liability arising from fraudulent or illegal activity by its employees, contractors, consultants and others; that the Company may experience breaches of security at its facilities or losses as a result of the theft of its products; risks related to the Company’s information technology systems; that the Company may be unable to sustain its revenue growth and development; that the Company may be unable to expand its operations quickly enough to meet demand or manage its operations beyond their current scale; that the Company may be unable to secure adequate or reliable sources of necessary funding; risk related to the available funds of the Company and the use of such funds; risks related to, or associated with, the Company’s exposure to reporting requirements; risks related to conflicts of interest; risks related to the reliance on the expertise and judgment of senior management of the Company, and ability to retain such senior management; risks related to the management of growth; risk of litigation; risks related to energy costs; risks related to fluctuations in foreign currency exchange rates; risks related to the Company’s potential exposure to greater-than-anticipated tax liabilities; risks related to the protection and enforcement of the Company’s intellectual property rights, or the intellectual property that it licenses from others; that the Company may become subject to allegations that it or its licensors are in violation of the intellectual property rights of third parties; that the Company may not realize the full benefit of the clinical trials or studies that it participates in; that the Company may not realize the full benefit of its licenses if the licensed material has less market appeal than expected and the licenses may not be profitable; and any other risks that may be included in the Filings. Although management has attempted to identify important risk factors that could cause actual results to differ materially from those contained in the forward-looking information in this presentation, there may be other risk factors not presently known to the Company or that the Company presently believes are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information in this presentation. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers and viewers should not place undue reliance on forward-looking information, which speaks only as of the date

  • made. The forward-looking information contained in this presentation represents the Company’s expectations as of the date of this presentation or the date indicated, regardless of the time of delivery of the presentation. The Company disclaims any intention,
  • bligation or undertaking to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required under applicable securities laws.

All of the forward-looking information contained in this presentation is expressly qualified by the foregoing cautionary statements. Investors and potential investors should consult their own professional advisors to ascertain and assess the income tax, legal, risk factors and other aspects of their investment or potential investment in the Company and should carefully consider the risks described in the Filings. Third Party Information The information contained in this presentation, including information provided by third parties, has not been independently verified and no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness, correctness or timeliness of the information or opinions expressed herein.

slide-3
SLIDE 3

p.3

SEPTEMBER 2019

  • p. 3

P R I V A T E & C O N F I D E N T I A L A P R I L 2 0 1 9 NOVEMBER 2019

  • p. 3

US$57.8B

Total addressable market

  • pportunity that

TerrAscend is well positioned to capture with access to three of the world’s largest markets for cannabis

2024E

United States

$11.0B $40.6B

24.4% CAGR

2018

Canada

$0.6B $5.2B

44.4% CAGR European Union(1)

$0.3B $12.0B

83.2% CAGR

Sources: Bloomberg, MarketWatch, Brightfield Group (1) Dollar values based on 1:1.1 conversion rate of EUR:USD

(Market values in USD)

slide-4
SLIDE 4

p.4

SEPTEMBER 2019

  • p. 4

P R I V A T E & C O N F I D E N T I A L A P R I L 2 0 1 9 NOVEMBER 2019

  • p. 4

(1) Metrics presented on a pro forma basis for pending acquisitions (2) Share price as of November 19, 2019 and shares as of September 30, 2019 (inclusive of all potentially dilutive securities)

Investment Highlights

Access to three of the world’s largest cannabinoid markets with strong foothold in the U.S. and Canada, as well as distribution capabilities to the European Union Growing portfolio of premium consumer-facing brands and products Uniquely positioned for growth with a four-pronged business model that includes Multi- State Operator (MSO) platform in the U.S. and Canadian Licensed Production (LP) Experienced leadership team with deep roots and track record in life sciences, highly regulated industries, and consumer products Proven consolidator with M&A expertise in the highly fragmented U.S. cannabis industry A global cannabinoid company, committed to scientific innovation and operational integrity

5

Retail Dispensaries

7

Owned Brands

225K+

  • Sq. ft. of Cultivation

& Production under Development

~53%

QoQ Revenue Growth

Key Metrics(1)

~$27M

Reported Q3 2019 Revenue

$679M

Fully Diluted Market Cap(2)

500+

Employees

10,000+

Store Distribution Network for CBD

110K+

  • Sq. ft. of Cultivation

& Production

Leading platform for innovation in drug development, R&D, and plant science

4

States in U.S. with Footprint

slide-5
SLIDE 5

p.5

SEPTEMBER 2019

  • p. 5

P R I V A T E & C O N F I D E N T I A L A P R I L 2 0 1 9 NOVEMBER 2019

  • p. 5

Canadian Licensed Producer (LP) with Global Distribution

Growing U.S. Footprint with Selective Vertical Integration Canadian Operations with Platform for Global Distribution

Nationwide distribution network for CBD products and brands

PA CA NV NJ Nationwide

Drug Development and R&D Platform Hemp-Derived CBD Brand Development and Distribution U.S. Multi-State Operator (MSO)

Unique Four-Pronged Business Model

TerrAscend has 1 of only 11 facilities in the world with an EU-Good Manufacturing Practices (EU-GMP) certificate enabling distribution to European consumers EU GMP standards for pharmaceuticals are among the most rigorous in the world, demanding the highest level of quality assurance and product consistency

Cultivation Distribution Production R&D

Mississauga, ON

Cultivation Distribution Production Retail Cultivation Distribution Production Retail Distribution Cultivation Distribution Production Retail Cultivation Distribution Production Retail Under Development Operational Legend

slide-6
SLIDE 6

p.6

SEPTEMBER 2019

  • p. 6

P R I V A T E & C O N F I D E N T I A L A P R I L 2 0 1 9 NOVEMBER 2019

  • p. 6

20+ years of experience in strategic management consulting, finance, structured credit solutions, capital markets sales, and debt and equity investing for the legal cannabis market 20+ years of experience in finance, investor relations, process re- engineering, accounting,

  • perations, loyalty and

consumer insights, M&A and merger integration 12+ years of experience in patient care, quality assurance, medical and regulatory affairs, and pharmaceutical research & development 13+ years of experience in human resources,

  • perational execution,

and strategic leadership within the retail and manufacturing sectors 20+ years of legal experience advising on transactions, securities regulation, and corporate governance / compliance

Adam Kozak

Chief Financial Officer

  • Dr. Michael Nashat

CEO, Co-Founder & Director

Jason Ackerman

Executive Chairman

Heather Molloy

Chief Strategy Officer

Joanna Halligan

VP, Human Resources

Brian Feldman

General Counsel 30+ years of experience, inclusive of executive leadership roles

  • perating consumer-

centric businesses, and brings deep experience across retail e- commerce, strategy, and logistics

slide-7
SLIDE 7

p.7

SEPTEMBER 2019

  • p. 7

P R I V A T E & C O N F I D E N T I A L A P R I L 2 0 1 9 NOVEMBER 2019

  • p. 7
  • President and Chief Investment Officer of JW Asset Management,

which he founded in 1998. Strong track record in finding and developing opportunities within the specialty pharmaceutical sector with >US$1B AUM

  • One of largest institutional investors in cannabis with ~$500M AUM
  • Chairman of Arbor Pharmaceuticals, growing revenue from $2M to

~US$300M in four years

Jason Wild, Chairman

  • Founder and former CEO of FreshDirect, a pure-play home delivery

grocer that he grew to >US$600M in annual sales in 7 U.S. states

  • 30+ years experience in retail e-commerce and operationalizing

strategy, with deep knowledge of operations, logistics & technology

  • Senior Advisor at The Boston Consulting Group and actively involved in

digital transformation and strategies

Jason Ackerman, Executive Chairman

  • 12+ years of experience in patient care, quality assurance, medical

and regulatory affairs, and pharmaceutical research & development

  • Co-Founder of OnPharm Independent Pharmacy Group, representing

>500 pharmacies with annual sales >$400M

  • Doctorate of Pharmacy from Albany College of Pharmacy and Health

Sciences

  • Dr. Michael Nashat, CEO, Co-Founder & Director
  • Previously held senior financial positions with several of Canada’s

largest publicly traded corporations

  • Advised middle-market privately held companies in both the United

States and Canada

Lisa Swartzman, Director

  • CEO of Veloxis Pharmaceuticals, a commercial-stage specialty

pharmaceutical company committed to improving the lives of transplant patients

  • 20+ years of experience in the pharmaceutical industry
  • Founder and former CEO of Cornerstone Therapeutics, a company

focused on hospital, respiratory, and adjacent specialty markets

  • Director of Opiant Pharmaceuticals, BioMark Pharmaceuticals, and

Hilltop Home Foundation

Craig Collard, Director

  • Former CFO of George Weston and EVP of Loblaw Companies
  • 25+ years experience in public company finance and strategy
  • Director of Roots Corporation and Canopy Rivers Corporation

Richard Mavrinac, Director

slide-8
SLIDE 8

p.8

SEPTEMBER 2019

  • p. 8

P R I V A T E & C O N F I D E N T I A L A P R I L 2 0 1 9

  • p. 8

NOVEMBER 2019

O U R E X P E R I E N C E O U R P A R T N E R S

Team brings strong, diversified pedigree with deep expertise

slide-9
SLIDE 9

p.9

SEPTEMBER 2019

  • p. 9

P R I V A T E & C O N F I D E N T I A L A P R I L 2 0 1 9

  • p. 9

NOVEMBER 2019

U.S. Multi-State Operator (MSO)

  • Acquired The Apothecarium and Ilera Healthcare as

foundations of vertically integrated U.S. operations

  • Selected to apply for one of six vertically integrated

permits in New Jersey

  • Own and operate cultivation facilities, processing,

product development, distribution, and retail

Canadian Licensed Producer (LP) with Global Distribution

  • Canadian LP with a 67,300 sq. ft. cultivation and

processing facility

  • Wholesale supply agreements in seven provinces,

reaching over 25M Canadians

  • GMP-EU designation provides platform for distribution,

potential to reach 279M European consumers

Hemp-Derived CBD Brand Development and Distribution Network

  • Acquired Arise Bioscience, a leading hemp-derived

CBD product developer

  • Distribution platform with access to over 10,000 retail

locations nationwide

Drug Development, R&D Platform, and Plant Science

  • Drug Preparation Premises (DPP) facility developing

formulations to meet institutional and consumer demands

  • Genetic program comprised of cutting-edge

genomics and molecular technologies, capable of bioengineering next-generation cannabis plants

slide-10
SLIDE 10

p.10

SEPTEMBER 2019

  • p. 10

P R I V A T E & C O N F I D E N T I A L A P R I L 2 0 1 9 NOVEMBER 2019

  • p. 10

Company Geography Overview Transaction Value(1) (USD) Status Nationwide Distribution Industry leader in the production and distribution of hemp-derived health and wellness products $13.0M Closed Jan. 2019 California Recognized as one of the nation’s premier chain of dispensaries with multiple locations in California $72.5M Closed May 2019 California Cannabis brand focused on the cultivation of ultra-premium flowers $2.9M Signed Aug. 2019 Expected close of Q4 2019 Pennsylvania One of five vertically integrated cannabis cultivator, processor, and dispensary operators in Pennsylvania $125.0M Closed Sep. 2019 Nevada Vertically integrated operation in Nevada with cultivation, edible manufacturing and a retail location $35.5M Signed Feb. 2019 Expected close of Q4 2019

Significant Opportunities for… M&A Transactions to Date

  • Geographic expansion and diversification
  • Accelerated market access for brands

and formulations of both TerrAscend and target companies

  • Partnering with experienced

management teams and industry experts

  • Expedited growth and operating

efficiencies through economies of scale

With Proven Ability to Execute

  • Management has expertise in acquiring and

integrating businesses

  • Robust and proprietary pipeline of
  • pportunities
  • ~US$250M cumulative transaction value of

acquisitions(1)

  • 4 strategic acquisitions signed or closed in

last 10 months

(California Entities) (Nevada Entity) (1) Transaction values exclude consideration contingent on future financial performance (2) Previously known as Grander Distribution (3) Represents transaction value to acquire 49.9% ownership stake of ABI SF (4) Estimated for illustrative purposes based on TerrAscend’s share price as of November 19, 2019

(2) (3) (4)

slide-11
SLIDE 11

p.11

SEPTEMBER 2019

  • p. 11

P R I V A T E & C O N F I D E N T I A L A P R I L 2 0 1 9

  • p. 11

NOVEMBER 2019

Named the best-designed dispensary in the country by Architectural Digest Three retail stores in California and one retail store in Nevada generated ~US$45M revenue in 2018 Awarded regulatory approval in February for fifth location in Berkeley, CA on high-foot traffic Telegraph Avenue. Construction expected to commence in Q4 2019 Additional retail license for undisclosed location in California and dispensary currently under construction in New Jersey Data-backed insights into customer purchasing patterns TerrAscend to leverage iconic brand and store model in

  • ther geographies across the United States
slide-12
SLIDE 12

p.12

SEPTEMBER 2019

  • p. 12

P R I V A T E & C O N F I D E N T I A L A P R I L 2 0 1 9

  • p. 12

NOVEMBER 2019

One of five permitted vertically integrated cannabis cultivator, processor, and dispensary operators in Pennsylvania Dispensary in Plymouth Meeting, PA with rights to open two additional dispensaries in the Philadelphia area 67,000 sq. ft. facility operating at full capacity with an expansion to 127,000 sq. ft. under construction(1) that will result in over 80,000 sq. ft. of total canopy space

  • State-of-the-art greenhouse designed for optimal plant growth
  • Cultivation and processing facility with a genetic library of over

170 cannabis strains

  • Significant market share in Pennsylvania’s limited license market

Ilera distributes its products to 70 of 72 medical cannabis dispensaries

  • Maintained experienced management team with operating

expertise and intellectual property knowledge-base

  • Highly accretive to TerrAscend’s margin profile

(1) Expected completion December 2019 / January 2020

slide-13
SLIDE 13

p.13

SEPTEMBER 2019

  • p. 13

P R I V A T E & C O N F I D E N T I A L A P R I L 2 0 1 9 NOVEMBER 2019

  • p. 13

One of only six new entities — out of 146 applicants — chosen for a vertically integrated permit in New Jersey 16-acre site with up to 200,000 sq. ft. of cultivation and processing, with 80,000 sq. ft. in initial phase(1) The Apothecarium dispensary will be located in Phillipsburg, NJ; sales expected to begin 1H 2020(1)

  • First-mover advantage in establishing New Jersey footprint

Per State regulators, TerrAscend has progressed the furthest toward commencing operations out of the six applicants

  • The Apothecarium dispensary under construction in Phillipsburg

will be the first medical dispensary in Warren County

  • The North Jersey region has the highest density of medical

patients in New Jersey, totaling 32,800 registered patients

Over 53,000 patients, 2,000 caregivers and 1,000 physicians are now participating in the program

  • Personal use legalization to be on the ballot in November 2020

A limited license market with recreational legalization on the horizon

(1) Initial phase under construction

slide-14
SLIDE 14

p.14

SEPTEMBER 2019

  • p. 14

P R I V A T E & C O N F I D E N T I A L A P R I L 2 0 1 9 NOVEMBER 2019

  • p. 14

US$20B hemp-derived CBD

  • pportunity in the U.S.(1)

Rapid new product & brand development Strong, established supply base

p . 1 4

  • 50+ SKUs, including tinctures,

edibles, and vapes

  • Strong recognition with Gen X

and young adults

  • Significant traction in

convenience stores, smoke and vape shops

  • 15+ SKUs, including formulated

gel caps and tinctures

  • Universal appeal across

customer segments

  • Expansion into natural foods

as well as health and wellness channels

(1) Projected product sales for 2024 per Arcview Market Research and BDS Analytics

slide-15
SLIDE 15

p.15

SEPTEMBER 2019

  • p. 15

P R I V A T E & C O N F I D E N T I A L A P R I L 2 0 1 9 NOVEMBER 2019

  • p. 15
  • 67,300 sq. ft. production and manufacturing facility

Licensed production area of 51,800 sq. ft.

Substantial capacity to manufacture and package quality cannabinoid products for medical and adult-use consumers

  • Products available through lucrative adult-use stream

Access to more than 70% (25M) of the Canadian population

Licensed to sell oils, extracts, topicals and edibles in addition to flower from EU-GMP certified Mississauga, ON facility

  • Cultivation in-house and through strategic partners

In-house cultivation earmarked for international export

Multi-year supply agreement with PharmHouse (1.3 million

  • sq. ft. of cultivation with 20% dedicated to TerrAscend)

Providing quality, pharmaceutical-grade products to 25M people

slide-16
SLIDE 16

p.16

SEPTEMBER 2019

  • p. 16

P R I V A T E & C O N F I D E N T I A L A P R I L 2 0 1 9 NOVEMBER 2019

  • p. 16

TerrAscend is creating unmatched scientific capabilities in the cannabis industry

  • Cannabis biotechnology and

licensing company committed to the continuous improvement of the cannabis plant through the application of cutting-edge genetics, chemistry and bioengineering technology

  • Brings together many of Canada’s

top plant biotechnologists and business leaders that are committed to solving the biggest challenges facing the fast-growing global cannabis industry

  • The industry’s first Drug Preparation

Premises (DPP) facility will allow TerrAscend to innovate and produce specialized pharmaceutical products for healthcare professionals and institutions

  • To deliver formulations that will

address unmet medical needs where no commercial product is

  • therwise available
  • Further positions TerrAscend as a

leading medical cannabis company in the field of personalized medicine

Ascendant Laboratories Solace Rx

slide-17
SLIDE 17

p.17

SEPTEMBER 2019

  • p. 17

P R I V A T E & C O N F I D E N T I A L A P R I L 2 0 1 9 NOVEMBER 2019

  • p. 17

Bringing our quality brands and formulations into thousands of retail channels

Unique formulas pairing high quality whole plant CBD extracts with clinically studied ingredients to maximize effects Founded in quality and the pursuit of innovation, Haven

  • St. offers a curated

collection of products, segmented by five consumer need states: Peace, Reset, Focus, Drift, and Rise Flavorful and affordable CBD products including gel caps, cartridges, gummies and tinctures A boutique brand with a focus on premium indoor cultivated flower, State Flower curates unique genetics with various attributes and effects High-quality, handcrafted artisan gummies that were created out of a desire for a low-dose and consistent product Formulations designed with precise ratios of cannabinoids, flavonoids, and terpenes to create the ideal therapeutic experience Knüba is committed to simplifying choices for patients to help them take charge of their health with the right products

slide-18
SLIDE 18

p.18

SEPTEMBER 2019

  • p. 18

P R I V A T E & C O N F I D E N T I A L A P R I L 2 0 1 9 NOVEMBER 2019

  • p. 18

<$0.0 $1.8 $5.0 $14.6 $17.6 $26.8 $0 $5 $10 $15 $20 $25 $30 Q2 2018 Q3 2018 Q4 2018 Q1 2019 Q2 2019 Q3 2019

  • Nov. 27, 2018

Revenue growth driven by execution of M&A strategy and organic initiatives

Over 1,400%

Growth ($ in millions) Shareholders approved U.S. expansion to pursue growth

  • pportunities including

strategic acquisitions

slide-19
SLIDE 19

p.19

SEPTEMBER 2019

  • p. 19

P R I V A T E & C O N F I D E N T I A L A P R I L 2 0 1 9 NOVEMBER 2019

  • p. 19

Fully Diluted Share Count(1)

Common Shares Outstanding 53.4 Proportionate Voting Shares (as converted)(3) 75.4 Total Basic Shares Outstanding 128.8 Non-Voting Exchangeable Shares(4) 38.9 Options for Common Shares 11.3 Warrants for Common Shares 0.4 Warrants for Proportionate Voting Shares (as converted)(3) 8.6 Fully Diluted Shares Outstanding 187.9 Share Issuance Pending Acquisition(5) 0.6 Pro Forma Fully Diluted Shares Outstanding 188.6

Key Metrics

Exchange / Ticker CSE: TER Share Price(2) $3.60 52-Week High / Low(2) $9.18 / $3.39 Fully Diluted Market Capitalization $678.9 Cash & Cash Equivalents(1) $6.9 Total Debt (excl. Lease Liability)(1) $233.2 Non-Controlling Interest(1) $3.9

($ and shares in millions, except share prices)

(1) As of September 30, 2019 (2) As of November 19, 2019 (3) Proportionate Voting Shares are exchangeable on a 1:1,000 basis for Common Shares (4) Exchangeable on a 1:1 basis for Common Shares. Non-voting and non-participating and may not be exchanged into Common Shares until certain regulatory and legal restrictions related to U.S. cannabis operations have been lifted (5) Represents shares to be issued as consideration for acquisition signed but not yet closed

slide-20
SLIDE 20

p.20

SEPTEMBER 2019

CONTACT

Adam Kozak Chief Financial Officer ir@terrascend.com 905-273-3792